3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Hodgkin Disease
11
Neoplasms
2
Mycosis Fungoides
2
Squamous Cell Carcinoma of Head and Neck
1
Sezary Syndrome
1
Mesothelioma, Malignant
1
Melanoma
1
Lymphomatoid Papulosis
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma, Large B-Cell, Diffuse
1
Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Cyclophosphamide
27
fludarabine
19
Dexamethasone
18
pembrolizumab
12
Rituximab
12
Etoposide
11
venetoclax
10
pomalidomide
9
Gemcitabine
9
Lenalidomide
8
fludarabine phosphate
7
daratumumab
7
Bortezomib
7
glofitamab
6
carfilzomib
6
Vincristine
6
obinutuzumab
5
Temozolomide
5
Prednisone
5
Nivolumab
5
Immunotherapy, Adoptive
5
Doxorubicin
5
Cytarabine
5
Cisplatin
5
Calcium Dobesilate
5
selinexor
4
cemiplimab
4
Carboplatin
4
Azacitidine
4
zanubrutinib
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Recurrence
×
Brentuximab Vedotin
×
90 days
×
Clear all
No trials found.